An International Approach With its head office in Berlin, branch offices in Munich and Buenos Aires CH KILGER offers a truly international approach providing a global IP service to its clients. The Munich office serves also for the preparation of the frequent oral proceedings CH KILGER takes part in. In Buenos Aires CH KILGER coordinates its Latin America services. The patent attorneys are highly specialized and strategic in their approach. A Wingspan of Expertise CH KILGER provides IP services ranging from trademark and patent prosecution, patent infringement and litigation, due diligence work, freedom-to-operate analyses, to opinion work and IP-sales/licensing transactions. CH KILGER can assist you in all technical areas such as the chemical, electrical, nanotechnology, food, biotechnology and pharmaceutical or the engineering fields. Strong scientific backgrounds, as well as years of legal experience working with the European Patent Office, the Latin American patent offices, top-tier international law firms and in-house counsel, mean the CH KILGER lawyers understand their technical, business, and legal goals. Our interdisciplinary approach leads to best possible synergies for our clients. Our Clients and Colleagues CH KILGER represents an international clientele of inventors as well as investors working with the most recent high-tech technologies. The clients range from multinational pharmaceutical corporations to start ups in various fields such as nanotechnology, microfluidics, polymer chemistry and biotechnology. Clients and colleagues have praised the firm for its exquisite work.
Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. | Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Ceragem Co., Ltd.
Founded in 1998, CERAGEM is the global home wellness solution provider within more than 70 countries. With the philosophy of health care management begins at home, we provide innovative wellness products and services for your everyday. We bring health to your home and build healthy habits to shape your fulfilling life.
Centre for Virology, Vaccinology and Therapeutics
The Centre for Virology, Vaccinology, and Therapeutics (CVVT), established in 2020 with the University of Hong Kong, is dedicated to reducing the health and economic impacts of future outbreaks. By pioneering rapid diagnostics, potent antimicrobials, and advanced vaccines, CVVT tackles endemic diseases in peacetime and prepares the world for epidemics and pandemics. Serving as a crucial bridge between foundational research and transformative technologies, CVVT cultivates a dynamic startup ecosystem focused on innovative solutions for infectious diseases and global health advancements. At this exhibition, discover our innovative startups: • Orimmune BioTech Limited, introducing its revolutionary Δ42PD1-specific antibody drug, set to redefine cancer immunotherapy with a novel immune-modulatory approach. • Antenovus Biotechnology Limited, combating antimicrobial resistance (AMR) with antivirulence therapies and antibiotic adjuvants targeting pathogens like MRSA. • Hong Kong Universal Vaccine Limited, unveiling its next-generation inhaled powder vaccine for children and elderly, offering needle-free mucosal immunity against influenza, COVID, and RSV. • BiomOrgan Limited, showcasing the world’s first human respiratory organoid culture system, transforming drug development and virus research. Visit our booth to explore how CVVT converts visionary research into practical solutions, enhancing global health resilience and positioning Hong Kong as a biotechnology hub against emerging infectious threats.
Centre for Translational Stem Cell Biology
Centre for Translational Stem Cell Biology (CTSCB) provides Hong Kong with an opportunity to excel in scientific and medical research. A team of top-notch scientists and clinicians from the University of Hong Kong and the University of Cambridge collaborates to elevate stem cell technology to new heights. By leveraging a pioneering patented technology, Expanded Potential Stem Cells (EPSCs), CTSCB is dedicated to advancing fundamental research and translating discoveries into regenerative medicine, organ transplantation and genomic medicine for the benefit of people worldwide. CTSCB primarily focuses on producing mature and functional cells for regenerative medicine with the patented technology, enabling in-depth study of immune disease mechanism, and expediting the development of antiviral, anti-ageing natural products and antibody drugs. Our vision is to translate medical discoveries and homegrown technologies into applications that not only serve medical and biotechnological purposes but also extend to the agricultural sector, fostering the growth of innovation and technology. | Imagine a future where healthcare is transformed by cutting-edge stem cell technology. Centre for Translational Stem Cell Biology (CTSCB), a collaboration between the University of Hong Kong and the University of Cambridge, supported by the Innovation and Technology Commission, is at the forefront of making this vision a reality. Leveraging patented Expanded Potential Stem Cell (EPSC) technology, we can create any cell type, both embryonic and extra-embryonic, offering immense potential for regenerative medicine and therapeutic applications. Our research focuses on intelligent drug screening, precision medicine and cell-based therapies. We develop next-generation stem cell technology that improves patient outcomes and enhances quality of life. Our drug screening platforms support pharmaceutical and health supplement companies in streamlining their development processes using multicellular organoid systems and personalized disease modelling. We also explore health and cosmetic products derived from EPSC technology, with interests in product co-development to address various health issues. By attracting top global talent and fostering innovation, CTSCB is well-positioned to enhance therapeutic applications and promote longevity. Through our innovative research and commitment to excellence, CTSCB aims to lead the way in revolutionary healthcare solutions for generations to come.
Center for Natural Product Systems Biology
The Center for Natural Product Systems Biology advances research through big data and AI to enhance R&D capabilities in natural product technologies. We study natural product-microbiome interactions by generating integrated omics data including compound, genomic, proteomic, transcriptomic, and metabolomic analyses.
Center for Electrochemical Energy Storage
The Center for Electrochemical Energy Storage | Ulm & Karlsruhe (CELEST) provides a broad platform for scientific collaboration, (science) communication, qualification of students’ and technology transfer in the field of electrochemical energy storage (EES) ranging from fundamental research to application as well as sustainability issues. Research fields of CELEST members include Li-, post-Li-batteries and alternative electrochemical energy storage conversion systems. The Cluster of Excellence POLiS (Post Lithium Storage) is one of CELEST‘s main activities in the post-lithium area: The focus is on sustainable alternatives based on sodium, potassium, magnesium, calcium, aluminium and chloride ions.